Companies /Healthcare

Tandem Diabetes Care Inc

NASDAQ: TNDM Medical Devices
$18.48
▼ $1.59 (−7.92%) today
Markets open · 4:18pm ET

TNDM at a Glance

Valuation
Market cap
$1.4B
Profitability
Revenue (TTM)
$1.1B
Profit margin
-4.6%
EPS (TTM)
$-0.70
Price
52-week range
$12 – $30
Street target
$26.90

Headquartered in San Diego, CA Fiscal year ends December NASDAQ: TNDM tandemdiabetes.com

About Tandem Diabetes Care

Tandem Diabetes Care is a global insulin delivery and diabetes technology company. It manufactures and sells automated insulin delivery systems for people with diabetes.

Its pump portfolio includes the Tandem Mobi system and the t:slim X2 insulin pump. Both run Control-IQ+ advanced hybrid closed-loop technology, which works with third-party continuous glucose monitors, including the Abbott FreeStyle Libre 3 Plus sensor in international markets.

Revenue comes from two sources:
- Pump sales.
- Recurring supplies and other sales, such as infusion sets and cartridges.

In the U.S., the company is shifting toward a pay-as-you-go pharmacy channel reimbursement model, which accounted for 15% of U.S. sales in Q3 2026.

Internationally, Tandem sells in numerous markets and is moving to direct operations in certain countries. It reports results across two geographies: the United States and International. Updated

Latest Activity

TNDMTandem Diabetes Care
Q3 2026
EPS
-$0.10
est -$0.24+58.4%
Revenue
$284M
est $266M+6.7%

Tandem is within striking distance of breakeven: the operating loss narrowed to $2.4 million from $22.9 million a year ago. Full-year guidance of $1.065 billion to $1.085 billion was reaffirmed.

Quarterly EPS — reported vs estimate

TNDM Coverage

Frequently Asked Questions

What does Tandem Diabetes Care do?

Tandem Diabetes Care is a global insulin delivery and diabetes technology company. It manufactures and sells automated insulin delivery systems for people with diabetes.

What is the TNDM stock price target?

The Wall Street consensus 12-month price target for TNDM is $26.90.